Abstract:The novelty of new human coronavirus COVID-19/SARS-CoV-2 and the lack of effective drugs and vaccines gave rise to a wide variety of strategies employed to fight this worldwide pandemic. Many of these strategies rely on the repositioning of existing drugs that could shorten the time and reduce the cost compared to de novo drug discovery. In this study, we presented a new network-based algorithm for drug repositioning, called SAveRUNNER (Searching off-lAbel dRUg aNd NEtwoRk), which predicts drug–disease associations by quantifying the interplay between the drug targets and the disease-specific proteins in the human interactome via a novel network-based similarity measure that prioritizes associations between drugs and diseases locating in the same network neighborhoods. Specifically, we applied SAveRUNNER on a panel of 14 selected diseases with a consolidated knowledge about their disease-causing genes and that have been found to be related to COVID-19 for genetic similarity (i.e., SARS), comorbidity (e.g., cardiovascular diseases), or for their association to drugs tentatively repurposed to treat COVID-19 (e.g., malaria, HIV, rheumatoid arthritis). Focusing specifically on SARS subnetwork, we identified 282 repurposable drugs, including some the most rumored off-label drugs for COVID-19 treatments (e.g., chloroquine , hydroxychloroquine , tocilizumab , heparin ), as well as a new combination therapy of 5 drugs ( hydroxychloroquine , chloroquine , lopinavir , ritonavir , remdesivir ), actually used in clinical practice. Furthermore, to maximize the efficiency of putative downstream validation experiments, we prioritized 24 potential anti-SARS-CoV repurposable drugs based on their network-based similarity values. These top-ranked drugs include ACE-inhibitors, monoclonal antibodies (e.g., anti-IFNγ, anti-TNFα, anti-IL12, anti-IL1β, anti-IL6), and thrombin inhibitors. Finally, our findings were in-silico validated by performing a gene set enrichment analysis, which confirmed that most of the network-predicted repurposable drugs may have a potential treatment effect against human coronavirus infections.

Network medicine framework for identifying drug-repurposing opportunities for COVID-19

SAveRUNNER: A network-based algorithm for drug repurposing and its application to COVID-19

Network reinforcement driven drug repurposing for COVID-19 by exploiting disease-gene-drug associations

Drug repurposing prediction for COVID-19 using probabilistic networks and crowdsourced curation

Network analytics for drug repurposing in COVID-19

Drug Repurposing for COVID-19 Treatment by Integrating Network Pharmacology and Transcriptomics

Network-Based Approach to Repurpose Approved Drugs for COVID-19 by Integrating GWAS and Text Mining Data

Knowledge Graph-Based Approaches to Drug Repurposing for COVID-19

Artificial intelligence in COVID-19 drug repurposing

Drug Repurposing for the Treatment of COVID‐19: A Knowledge Graph Approach

Repurposing of Anti-Cancer Drugs Against Moderate and Severe COVID Infection: A Network-Based Systems Biological Approach

Drug repurposing for COVID-19 using graph neural network and harmonizing multiple evidence

Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning

Drug Repurposing for COVID-19: A Review and a Novel Strategy to Identify New Targets and Potential Drug Candidates

Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19

Recent computational drug repositioning strategies against SARS-CoV-2.

Identification of Therapeutic Drugs Against COVID-19 Through Computational Investigation on Drug Repurposing and Structural Modification

Are we there yet? Analyzing scientific research related to COVID-19 drug repurposing

SperoPredictor: An Integrated Machine Learning and Molecular Docking-Based Drug Repurposing Framework With Use Case of COVID-19

An in silico drug repurposing pipeline to identify drugs with the potential to inhibit SARS-CoV-2 replication

Drug repurposing platform for deciphering the druggable SARS-CoV-2 interactome